Conference Coverage

Improving Treatment Options for Chronic Myelogenous Leukemia

Dr. Benjamin Powers and Dr. Suman Kambhampati discuss the improvements they have seen in the survival of patients with CML and how genetics and other factors play a role in treating the disease.


 

Recently, Federal Practitioner talked with Benjamin Powers, MD, and Suman Kambhampati, MD, about factors that come into play when treating patients with chronic myelogenous leukemia (CML) and the dramatic improvements in treatment that have been made. To find out more about these factors and improvements, read Blast Phase Chronic Myelogenous Leukemia from the August 2014 issue.

Dr. Powers is a fellow and Dr. Kambhampati is an associate professor of medicine, both in the Department of Internal Medicine, Division of Hematology/Oncology, at the University of Kansas Medical Center in Kansas City, Kansas. Dr. Kambhampati is also a staff physician in the Hematology/Oncology Division at the Kansas City VAMC in Kansas City, Missouri.

Recommended Reading

Boosting Blood Cells for Transplant Patients
AVAHO
Squamous Cell Carcinoma of the Anus in a Patient with Chronic Lymphocytic Leukemia
AVAHO
Blast Phase Chronic Myelogenous Leukemia
AVAHO
Signaling Pathways and Novel Inhibitors in Chronic Lymphocytic Leukemia
AVAHO

Related Articles

  • Clinical Topics & News

    Blast Phase Chronic Myelogenous Leukemia

    The dramatic improvement in survival with tyrosine kinase inhibitors has not been demonstrated in the advanced blast phase of chronic myelogenous...